2022³â ´ëÇÑ°ñ´ë»çÇÐȸ Á¦6Â÷ °ñ´ë»çÁúȯ ½ÉÈ°úÁ¤- Bone Specialist Symposium - : 2022-01-15±³À°ÀÏÀÚ : 2022-01-15
±³À°Àå¼Ò : ½ºÀ§½º±×·£µåÈ£ÅÚ º»°ü 2Ãþ ±×·£µåº¼·ë
±³À°ÁÖÁ¦ :
2022³â ´ëÇÑ°ñ´ë»çÇÐȸ Á¦6Â÷ °ñ´ë»çÁúȯ ½ÉÈ°úÁ¤- Bone Specialist Symposium - ÁÖÃÖ±â°ü : ´ëÇÑ°ñ´ë»çÇÐȸ
´ã´çÀÚ : ÇÐȸ»ç¹«±¹
¿¬¶ôó : 02-3473-2230
À̸ÞÀÏ :
bone90@empal.com ±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ¼Ò¾Æû¼Ò³â°ú, »êºÎÀΰú, Á¤½Å°Ç°ÀÇÇаú, Á¤Çü¿Ü°ú, ½Å°æ¿Ü°ú, ÈäºÎ¿Ü°ú, ¼ºÇü¿Ü°ú, ¾È°ú, À̺ñÀÎÈÄ°ú, ÇǺΰú, ºñ´¢ÀÇÇаú, ¿µ»óÀÇÇаú, ¹æ»ç¼±Á¾¾çÇаú, ¸¶ÃëÅëÁõÀÇÇаú, ½Å°æ°ú, ÀçÈ°ÀÇÇаú, °áÇÙ°ú, Áø´Ü°Ë»çÀÇÇаú, º´¸®°ú, °¡Á¤ÀÇÇаú, »ê¾÷ÀÇÇаú, ÇÙÀÇÇаú, ÀÀ±ÞÀÇÇаúÀÇ»çÇÐ, ¹ýÀÇÇÐ, ¿¹¹æÀÇÇÐ, ÇغÎÇÐ, »ý¸®ÇÐ, »ýÈÇÐ, ºÐÀÚ»ý¹°ÇÐ, ¹Ì»ý¹°ÇÐ, ±â»ýÃæÇÐ, ¾à¸®ÇÐ, ÀÇ·á»çȸÇÐ, ÀÇ·áÀ±¸®ÇÐ, ÀÇ·á»çȸ½É¸®ÇÐ, ÀÇ·áÄ¿¹Â´ÏÄÉÀ̼Ç, ÀÇÇб³À°
Âü¼®¿¹»óÀοø : 80¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 6 ½Ã°£ 50ºÐ
¼¼ºÎ¼ö°·á : 50,000¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 01-15 ±×·£µåº¼·ëA 08:50~09:00 °³È¸»ç ÇѸíÈÆ(´ëÇÑ°ñ´ë»çÇÐȸ ȸÀå)
±³À°½Ã°£ 01-15 ±×·£µåº¼·ëA 09:00~09:25 Epidemiology and Characteristics About Osteoporotic Fracture ÀÌ¿µ±Õ(¼¿ïÀÇ´ë Á¤Çü¿Ü°ú)
±³À°½Ã°£ 01-15 ±×·£µåº¼·ëA 09:25~09:50 Appropriate Evaluation of BMD ±è´öÀ±(°æÈñÀÇ´ë ³»ºÐºñ³»°ú)
±³À°½Ã°£ 01-15 ±×·£µåº¼·ëA 09:50~10:15 Updates in Bone Turnover Markers ÀüÀ±°æ(ºÎ»êÀÇ´ë ³»ºÐºñ³»°ú)
±³À°½Ã°£ 01-15 ±×·£µåº¼·ëA 10:15~10:40 Bisphosphonates and Denosumab ¹é±âÇö(°¡Å縯ÀÇ´ë ³»ºÐºñ³»°ú)
±³À°½Ã°£ 01-15 ±×·£µåº¼·ëA 10:40~11:05 Teriparatide and Romosozumab ±è»ó¿Ï(¼¿ïÀÇ´ë ³»ºÐºñ³»°ú)
ÈÞ½Ä 01-15 ±×·£µåº¼·ëA 11:05~11:20 Break ¹× À̵¿ ()
±³À°½Ã°£ 01-15 ±×·£µåº¼·ëA 11:20~11:45 Hypercalcemia º¯µ¿¿ø(¼øõÇâÀÇ´ë ³»ºÐºñ³»°ú)
±³À°½Ã°£ 01-15 ±×·£µåº¼·ëB 11:20~11:45 Hypocalcemia À̽ÃÈÆ(°¡ÃµÀÇ´ë ³»ºÐºñ³»°ú)
±âŸ 01-15 ±×·£µåº¼·ëA 11:45~11:55 À̵¿ ()
±³À°½Ã°£ 01-15 ±×·£µåº¼·ëA 11:55~12:20 Genetic approach to rare bone disease °íÁ¤¹Î(¼¿ïÀÇ´ë ¼Ò¾Æû¼Ò³â°ú)
±³À°½Ã°£ 01-15 ±×·£µåº¼·ëB 11:55~12:20 Hypophosphatemia ÀÌÀ¯¹Ì(¿¬¼¼ÀÇ´ë ³»ºÐºñ³»°ú)
½Ä»ç 01-15 ±×·£µåº¼·ëA 12:20~13:20 Á¡½É ()
±³À°½Ã°£ 01-15 ±×·£µåº¼·ëA 13:20~13:45 ASBMR Highlights -Basic- ÃÖÁ¦¿ë(°æºÏÀÇ´ë »ýÈÇм¼Æ÷»ý¹°Çаú)
±³À°½Ã°£ 01-15 ±×·£µåº¼·ëA 13:45~14:10 ASBMR Highlights -Clinical- Á¤È£¿¬(°æÈñÀÇ´ë ³»ºÐºñ³»°ú)
±³À°½Ã°£ 01-15 ±×·£µåº¼·ëA 14:10~14:35 onpharmacological Management of Osteoporosis ÇÏ¿ëÂù(Áß¾ÓÀÇ´ë Á¤Çü¿Ü°ú)
±³À°½Ã°£ 01-15 ±×·£µåº¼·ëA 14:35~15:00 reat-to-Target Approach in Osteoporosis °íÁ¤¹Î(¿ï»êÀÇ´ë ³»ºÐºñ³»°ú)
±³À°½Ã°£ 01-15 ±×·£µåº¼·ëA 15:00~15:25 Advances in Sarcopenia Management Á¤Èñ¿ø(¿ï»êÀÇ´ë ³ë³â³»°ú)
ÈÞ½Ä 01-15 ±×·£µåº¼·ëA 15:25~15:40 Break ()
±³À°½Ã°£ 01-15 ±×·£µåº¼·ëA 15:40~16:00 Know-How of Hormone Replacement Therapy and SERM ½ÅÁ¤È£(°í·ÁÀÇ´ë »êºÎÀΰú)
±³À°½Ã°£ 01-15 ±×·£µåº¼·ëA 16:00~16:20 Management of Osteoporosis in Chronic Kidney Disease ±è¼¼È(°¡Å縯°üµ¿ÀÇ´ë ³»ºÐºñ³»°ú)
±³À°½Ã°£ 01-15 ±×·£µåº¼·ëA 16:20~16:40 Management of Glucocorticoid-Induced Osteoporosis ¼ºÀ±°æ(ÇѾçÀÇ´ë ·ù¸¶Æ¼½º³»°ú)
±âŸ 01-15 ±×·£µåº¼·ëA 16:40~16:50 Æóȸ»ç ÇÏ¿ëÂù(´ëÇÑ°ñ´ë»çÇÐȸ ÀÌ»çÀå)